Key Highlights

  • NextCure entered a definitive all-stock reverse merger with Avere Therapeutics, with the combined company trading under the new ticker Avere Therapeutics (NASDAQ: AVRX) under CEO Dr. Andrew Cheng.
  • Avere stockholders will own approximately 98.79% of the combined company, while legacy NextCure holders retain 1.21% ownership plus a two-year contingent value right (CVR) entitling them to 90% of proceeds from NextCure's legacy assets.
  • The deal is bolstered by a $320 million private placement led by Fairmount and Hansoh Pharma, providing capital to fund the combined company's pipeline.
  • This financing is expected to provide an operational runway through a Phase 2b psoriasis readout in early 2028 and the start of a Phase 2b ulcerative colitis trial.

NextCure, Inc. (NASDAQ: NXTC) has entered into a definitive all-stock reverse merger agreement with Avere Therapeutics, establishing a combined clinical-stage company that will trade under the new ticker Avere Therapeutics (NASDAQ: AVRX). The transaction, structured as a reverse merger, allows Avere to become a publicly traded company by combining with NextCure's existing public listing, a common structure used by private biotech companies seeking public market access without pursuing a traditional initial public offering.

The combined entity will operate under the leadership of CEO Dr. Andrew Cheng and will prioritize the development of AVR-001, a long-acting cyclic peptide IL-23 receptor antagonist that Avere has licensed from Hansoh Pharma. The ownership structure of the deal reflects Avere's position as the operating business driving the combined company's go-forward strategy: Avere stockholders will own approximately 98.79% of the combined entity, while legacy NextCure stockholders will retain a much smaller 1.21% ownership stake.

To provide additional value to legacy NextCure shareholders beyond the reduced equity stake, the transaction includes a two-year contingent value right (CVR) entitling those shareholders to 90% of any proceeds realized from NextCure's legacy pipeline assets. This CVR structure is a common mechanism in reverse merger transactions, allowing shareholders of the company being effectively absorbed to retain some economic upside from assets that will not be part of the combined company's forward-looking strategy, without requiring the new combined entity to directly fund or prioritize those legacy programs.

The transaction is supported by substantial new capital: a $320 million private placement led by Fairmount and Hansoh Pharma, the same company that licensed AVR-001 to Avere. This dual role for Hansoh, as both the licensor of the lead asset and a lead investor in the financing round, suggests a strong alignment of interest in the combined company's success and provides a vote of confidence from a party with direct knowledge of AVR-001's underlying science and competitive positioning.

This capital infusion is expected to fund the combined company's operations through key clinical milestones, specifically providing runway through a Phase 2b psoriasis readout expected in early 2028, as well as supporting the commencement of a separate Phase 2b trial in ulcerative colitis. Having capital secured through these two significant mid-stage clinical readouts gives the combined company meaningful visibility into its near-to-medium-term development pathway without an immediate need to return to capital markets.

For NextCure shareholders, the transaction represents a significant strategic pivot away from the company's prior pipeline and toward Avere's IL-23 receptor antagonist program, a common outcome for reverse mergers where a company's own pipeline has struggled to generate sufficient standalone value. The CVR structure offers a mechanism to preserve some value from NextCure's legacy assets, while the substantially larger ownership stake retained by Avere stockholders reflects the market's view of where the combined company's primary value proposition now resides.